Patients receiving extracorporeal membrane oxygenation (ECMO) are complex and drug dosing is complicated by significant pharmacokinetic alterations. We sought to describe the frequency of achievement of therapeutic vancomycin concentrations in critically ill patients receiving ECMO with therapeutic drug monitoring (TDM). In this retrospective observational study, we included all critically ill patients receiving TDM for vancomycin whilst on ECMO. The primary outcome was the proportion of plasma vancomycin concentrations in therapeutic range (15-20 mg/L). Factors associated with not achieving therapeutic concentrations were investigated, including ECMO duration and use of renal replacement therapies. Vancomycin TDM was performed in 77 of 116 (66%) patients on ECMO. Median (interquartile range) duration of ECMO support was 7 days (4-16). The proportion of measurements in the therapeutic range (15-20mg/L) was 24%, while 46% were subtherapeutic (<15mg/L) and 30% were supratherapeutic (>20mg/L). The proportion of measures in the therapeutic range was significantly higher on ECMO days for 6-13 (IRR: 2.4; 95% CI: 1.2-4.6; p=0.01). Supratherapeutic concentrations were more frequently observed in patients on RRT (IRR: 2.0; 95% CI 1.3-3.1; p= 0.002). The vancomycin concentrations in patients did not vary with age, gender or type of ECMO support. Patients receiving vancomycin had suboptimal concentrations early in the course of ECMO. Patients not receiving RRT and those with mild to moderate acute kidney injury (AKI) were at a risk of underdosing while those with established AKI on RRT may experience supratherapeutic concentrations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.